About VectoryTx
VectoryTx is a company based in Amsterdam (Netherlands) founded in 2020. VectoryTx has raised $175.55 million across 2 funding rounds from investors including Lilly, EQT and Benhamou Global Ventures. VectoryTx offers products and services including VTx-002, VTx-003, and Vectorized Antibody Platform. VectoryTx operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Senti Biosciences and MorphoSys, among others.
- Headquarter Amsterdam, Netherlands
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website vectorytx.com
- Social LinkedIn
- Total Equity Funding$175.55M (USD)
in 2 rounds
- Latest Funding Round$138M (USD), Series A
Nov 2023
- InvestorsLilly
& 7 more
Products & Services of VectoryTx
VectoryTx offers a comprehensive portfolio of products and services, including VTx-002, VTx-003, and Vectorized Antibody Platform.
Antibody treatment targeting Amyotrophic Lateral Sclerosis (ALS).
Antibody treatment for Huntington’s disease.
Technology for developing intracellular antibodies using AAV capsids.
Funding Insights of VectoryTx
VectoryTx has successfully raised a total of $175.55M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $138 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $175.55M
- Total Rounds 2
- Last Round Series A — $138M
- First Round $37.55M
(Jun 2021)
- Investors Count 8
All 2 funding rounds of VectoryTx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
8 investors in total: 8 institutional.
Investors in VectoryTx
VectoryTx has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, EQT and Benhamou Global Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Seed and early-stage therapeutics companies are invested in by MRLV. | – | mrlv.com | Cambridge, United States | |
Investment firm scaling software and technology companies from early to late stages. | – | insightpartners.com | - | |
A venture capital fund focused on biotech for neurodegeneration. | – | alsinvestmentfund.com | Amsterdam, Netherlands | |
Life science focused VC firm investing in startups in Europe | – | biogenerationventures.com | Naarden, Netherlands | |
Venture capital firm investing in AI and cross-border enterprise startups from Silicon Valley. | 2003 | benhamouglobalventures.com | Tel Aviv, Israel | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for VectoryTx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VectoryTx
20 people are tracked at VectoryTx (6 in leadership, 7 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Alexander Vos | CEO | Leadership |
Sander Van Deventer | CEO | Leadership |
Femke Hoeksema | Director PD | Leadership |
Barbara Sanders | VP, Vector Development | Leadership |
Adriaan de Wilde | Head Assay Development | Leadership |
Wouter Pos | Director of Antibody Technology | Leadership |
Jason Zhang | Non-Executive Director | Board & advisors |
Dmitrij Hristodorov | Observer | Board & advisors |
Lance Weed | Advisor | Board & advisors |
Hergen Spits | Advisor | Board & advisors |
Tim Luker | Observer | Board & advisors |
Oskar Slotboom | Observer | Board & advisors |
Frank S Walsh | Independent Board Member | Board & advisors |
Pavlina Konstantinova | CSO | Team |
Svetlana Pasteuning-Vuhman | Senior Scientist Gene Therapy | Team |
Astrid Coolen | Senior technician vector generation | Team |
Fadel Aljawaheri | Consultant DSP And Process Scale-up | Team |
Rob Haselberg | Patient Partnership [interim] | Team |
Kwankwan Zhu | Technician Research | Team |
Auriane Ernault | Scientist Vectorized Antibody Technologies | Team |
Complete people profiles for VectoryTx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VectoryTx
3 dated milestones of VectoryTx across 3 years, from founding to its latest funding, stage changes and deals.
- Founded VectoryTx is founded.
- Funding First funding round of $37.6M.
- Funding Latest funding round, Series A, of $138.0M.
Competitors of VectoryTx
VectoryTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Senti Biosciences and MorphoSys, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| sentibio.com | 2016 | San Francisco, United States | $158M | – | Cell-based therapies for cancer treatment are developed. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| genmab.com | 1999 | Copenhagen, Denmark | – | 1,212 | Antibody therapeutics for cancer and autoimmune diseases are developed. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of VectoryTx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VectoryTx
The website of VectoryTx (vectorytx.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▲ 24.9% vs previous month
Latest news on Vectorytx
Complete news archive for VectoryTx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to VectoryTx
10 companies that operate in the same segment as VectoryTx (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VectoryTx
VectoryTx was founded in 2020 and raised its 1st funding round 1 year after it was founded.
VectoryTx is headquartered in Amsterdam, Netherlands.
Alexander Vos is the current CEO of VectoryTx.
VectoryTx is a funded company, having raised a total of $175.55M across 2 funding rounds to date. The company's 1st funding round was a Seed of $37.55M, raised on Jun 2021.
VectoryTx was founded in 2020 in Amsterdam, Netherlands, within the biotechnology sector. Therapeutics for neurodegenerative and muscular disorders are developed, incorporating next-generation viral vectors that target specific cell types and subcellular compartments while avoiding host immune responses. The platform relies on AAV gene therapy, antibody technologies, and RNA-targeted degradation methods to advance treatments.
VectoryTx offers VTx-002, VTx-003, and Vectorized Antibody Platform.
VectoryTx has 8 investors. Key investors include Lilly, EQT, Benhamou Global Ventures, Forbion, and MRLV.